-
Mashup Score: 3
PURPOSEThe JCCG ALL-B12 clinical trial aimed to evaluate the effectiveness of unvalidated treatment phases for pediatric ALL and develop a safety-focused treatment framework.PATIENTS AND METHODSPatients age 1-19 years with newly diagnosed B-ALL were …JCCG ALL-B12: Evaluation of Intensified Therapies for Pediatric B-cell Acute Lymphoblastic Leukemia
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3
PURPOSEThe nodal burden of patients with residual isolated tumor cells (ITCs) in the sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC) (ypN0i+) is unknown, and axillary management is not standardized. We investigated rates of additional …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i1): The OPBC-05/ICARO Study. https://t.co/AKCvEKdZa8
-
-
Mashup Score: 3
PURPOSEPharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration–approved for adults.METHODSReNeu is an open-label, multicenter, pivotal, phase IIb …Mirdametinib demonstrated efficacy, improved pain/HRQoL, and safety in adults and children with NF1-PN in ReNeu.
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma: https://t.co/JZW8HsFEgP @moert001 #Neurofibromatosis
-
-
Mashup Score: 28JCO Oncology Advances | ASCO Publications - 12 day(s) ago
JCO Oncology Advances (JCO OA) is a fully open-access, online-only, and interdisciplinary journal committed to accelerating progress in the global fight against cancer. By providing a platform where innovation meets accessibility, JCO OA will be your premier destination for cutting-edge global clinical and translational research in the dynamic field of oncology. Trial-adjacent research that expands understanding beyond large trials such as therapeutic and supportive care trials Early phase clinical
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
📢Calling all oncology researchers! We’re accepting submissions for JCO Oncology Advances. Share impactful cancer research with a global community and contribute to advancing clinical oncology. Submit your work ➡️ https://t.co/X7kPzhIz2z #JCO #OncologyResearch #OpenAccess
-
-
Mashup Score: 9
PURPOSEThe clinical efficacy of total neoadjuvant therapy (TNT) followed by selective nonoperative management (NOM) for locally advanced rectal cancer (LARC) was examined in the Organ Preservation for Rectal Adenocarcinoma (OPRA) trial. We investigated …TNT with selective NOM is a cost-effective strategy for locally advanced rectal cancer
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Cost-Effectiveness of Total Neoadjuvant Therapy With Selective Nonoperative Management for Locally Advanced #RectalCancer: Analysis of Data From the Organ Preservation for Rectal Adenocarcinoma Trial: https://t.co/T2umEpR0B5 #CRCSM
-
-
Mashup Score: 13
PURPOSEAs part of the 100,000 Genomes Project, we set out to assess the potential viability and clinical impact of reporting genetic variants associated with drug-induced toxicity for patients with cancer recruited for whole-genome sequencing (WGS) as …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 #Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice https://t.co/RkQ0C6JwpC @EllieMcDonagh @QMUL @GenomicsEngland @emblebi
-
-
Mashup Score: 14Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer | Journal of Clinical Oncology - 18 day(s) ago
PURPOSEOrgan preservation has become an attractive alternative to surgery (total mesorectal excision [TME]) among patients with rectal cancer after neoadjuvant therapy who achieve a clinical complete response (cCR). Nearly 30% of these patients will …Increased risk of distant metastases with local regrowth after watch-and-wait for rectal cancer.
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Risks of Organ Preservation in #RectalCancer: Data From Two International Registries on Rectal Cancer https://t.co/dUTs94NIep @LauraFz_MD #crcsm
-
-
Mashup Score: 4Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer | Journal of Clinical Oncology - 19 day(s) ago
PURPOSEDespite advances in immunotherapy, unresectable recurrent/metastatic head and neck cancer (HNC) carries a poor prognosis, and effective treatments are needed. As nectin-4 is widely expressed in HNC, enfortumab vedotin (EV), a nectin-4–directed …
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced #HeadandNeckCancer: https://t.co/uOu4ca0OxJ #hnsm
-
-
Mashup Score: 14
PURPOSEBiliary tract cancers (BTCs) harbor an immunosuppressed tumor microenvironment and respond poorly to PD-1/PD-L1 inhibitors. Bevacizumab (anti–vascular endothelial growth factor) plus chemotherapy can promote anticancer immunity, augmenting response …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced #BiliaryTractCancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial https://t.co/o6sh3C7wWK #gicsm
-
-
Mashup Score: 1
PURPOSEHuman epidermal growth factor receptor 2 (HER2)–targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop progressive disease with persistent HER2 expression. No definitive treatment guidance currently …Treatment of patients with pretreated HER2+ MBC with T-Duo ADC versus physician’s choice in TULIP phase III trial.
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic #BreastCancer: An Open-Label, Randomized, Phase III Trial (TULIP) https://t.co/3yWNYLEutp #bcsm
-
JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL. #pedcsm #pedonc https://t.co/w3mWT3du39